JP5167389B2 - クエン酸第二鉄を含む錠剤 - Google Patents

クエン酸第二鉄を含む錠剤 Download PDF

Info

Publication number
JP5167389B2
JP5167389B2 JP2011151304A JP2011151304A JP5167389B2 JP 5167389 B2 JP5167389 B2 JP 5167389B2 JP 2011151304 A JP2011151304 A JP 2011151304A JP 2011151304 A JP2011151304 A JP 2011151304A JP 5167389 B2 JP5167389 B2 JP 5167389B2
Authority
JP
Japan
Prior art keywords
tablet
mass
manufactured
ferric citrate
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011151304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012031166A (ja
Inventor
正義 福島
一洋 織田
省吾 山根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Priority to JP2011151304A priority Critical patent/JP5167389B2/ja
Publication of JP2012031166A publication Critical patent/JP2012031166A/ja
Application granted granted Critical
Publication of JP5167389B2 publication Critical patent/JP5167389B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
JP2011151304A 2010-07-07 2011-07-07 クエン酸第二鉄を含む錠剤 Active JP5167389B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011151304A JP5167389B2 (ja) 2010-07-07 2011-07-07 クエン酸第二鉄を含む錠剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010155290 2010-07-07
JP2010155290 2010-07-07
JP2011151304A JP5167389B2 (ja) 2010-07-07 2011-07-07 クエン酸第二鉄を含む錠剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012278687A Division JP5902606B2 (ja) 2010-07-07 2012-12-20 クエン酸第二鉄を含む錠剤

Publications (2)

Publication Number Publication Date
JP2012031166A JP2012031166A (ja) 2012-02-16
JP5167389B2 true JP5167389B2 (ja) 2013-03-21

Family

ID=45441316

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2011151304A Active JP5167389B2 (ja) 2010-07-07 2011-07-07 クエン酸第二鉄を含む錠剤
JP2012278687A Active JP5902606B2 (ja) 2010-07-07 2012-12-20 クエン酸第二鉄を含む錠剤
JP2016047158A Active JP6321706B2 (ja) 2010-07-07 2016-03-10 クエン酸第二鉄を含む錠剤
JP2018073443A Active JP6571236B2 (ja) 2010-07-07 2018-04-05 クエン酸第二鉄を含む錠剤
JP2019145655A Pending JP2019189659A (ja) 2010-07-07 2019-08-07 クエン酸第二鉄を含む錠剤
JP2022088148A Active JP7395653B2 (ja) 2010-07-07 2022-05-31 クエン酸第二鉄を含む錠剤
JP2023201576A Pending JP2024015097A (ja) 2010-07-07 2023-11-29 クエン酸第二鉄を含む錠剤

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2012278687A Active JP5902606B2 (ja) 2010-07-07 2012-12-20 クエン酸第二鉄を含む錠剤
JP2016047158A Active JP6321706B2 (ja) 2010-07-07 2016-03-10 クエン酸第二鉄を含む錠剤
JP2018073443A Active JP6571236B2 (ja) 2010-07-07 2018-04-05 クエン酸第二鉄を含む錠剤
JP2019145655A Pending JP2019189659A (ja) 2010-07-07 2019-08-07 クエン酸第二鉄を含む錠剤
JP2022088148A Active JP7395653B2 (ja) 2010-07-07 2022-05-31 クエン酸第二鉄を含む錠剤
JP2023201576A Pending JP2024015097A (ja) 2010-07-07 2023-11-29 クエン酸第二鉄を含む錠剤

Country Status (4)

Country Link
US (1) US20220142926A1 (cg-RX-API-DMAC7.html)
EP (1) EP2594277A4 (cg-RX-API-DMAC7.html)
JP (7) JP5167389B2 (cg-RX-API-DMAC7.html)
WO (1) WO2012005340A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019189659A (ja) * 2010-07-07 2019-10-31 日本たばこ産業株式会社 クエン酸第二鉄を含む錠剤

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101665968B1 (ko) 2009-07-21 2016-10-13 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
EP3157516A4 (en) * 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
US20210085711A1 (en) * 2017-09-19 2021-03-25 Japan Tobacco Inc. Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
FR2774291B1 (fr) * 1998-02-03 2000-04-21 Innothera Lab Sa Specialite pharmaceutique sous forme galenique unitaire de comprimes a croquer ou a sucer, comprenant comme principe actif du fer element
WO2000054752A1 (fr) * 1999-03-15 2000-09-21 Kaken Pharmaceutical Co., Ltd. Comprimes a delitement rapide et procede de fabrication
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
KR101011373B1 (ko) 2002-07-11 2011-01-28 비큐론 파마슈티컬스 인코포레이티드 항균작용을 갖는 ｎ-히드록시아미드 유도체
EP1536788A1 (en) * 2002-08-30 2005-06-08 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
ES2395724T3 (es) * 2003-08-20 2013-02-14 Shionogi & Co., Ltd. Nueva composición de recubrimiento
JP4984455B2 (ja) * 2004-08-18 2012-07-25 日本新薬株式会社 二重被覆錠剤
JP2006076971A (ja) * 2004-09-13 2006-03-23 Basf Ag 口腔内崩壊錠
HUE025264T2 (en) * 2005-08-18 2016-02-29 Panion & Bf Biotech Inc Pharmaceutical-grade ferric citrate for medical use
HUE028029T2 (en) * 2006-01-30 2016-11-28 Panion & Bf Biotech Inc Method of treating chronic kidney disease
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
GB0714670D0 (en) * 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
JPWO2009057569A1 (ja) * 2007-10-29 2011-03-10 第一三共株式会社 フィルムコーティング製剤
WO2009101940A1 (ja) * 2008-02-11 2009-08-20 Dainippon Sumitomo Pharma Co., Ltd. 溶出性の改善された錠剤
JP2009269874A (ja) * 2008-05-09 2009-11-19 Daido Kasei Kogyo Kk 水性液剤
WO2012005340A1 (ja) * 2010-07-07 2012-01-12 日本たばこ産業株式会社 クエン酸第二鉄を含む錠剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019189659A (ja) * 2010-07-07 2019-10-31 日本たばこ産業株式会社 クエン酸第二鉄を含む錠剤

Also Published As

Publication number Publication date
JP7395653B2 (ja) 2023-12-11
JP2019189659A (ja) 2019-10-31
JP6321706B2 (ja) 2018-05-09
JP2016106145A (ja) 2016-06-16
JP2018104478A (ja) 2018-07-05
JP2013053168A (ja) 2013-03-21
EP2594277A1 (en) 2013-05-22
WO2012005340A1 (ja) 2012-01-12
JP2022107684A (ja) 2022-07-22
JP5902606B2 (ja) 2016-04-13
US20220142926A1 (en) 2022-05-12
JP6571236B2 (ja) 2019-09-04
JP2024015097A (ja) 2024-02-01
JP2012031166A (ja) 2012-02-16
EP2594277A4 (en) 2014-01-01

Similar Documents

Publication Publication Date Title
JP7395653B2 (ja) クエン酸第二鉄を含む錠剤
US20200163890A1 (en) Tablet containing ferric citrate
CN101945657B (zh) 具有改善的溶出性的片剂
IL217637A (en) Ferric citrate dosage forms
JP2017190325A (ja) 化学的な安定性を改善した、非晶質体ソリフェナシン含有製剤
US20140341993A1 (en) Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method of production thereof
CN102958514A (zh) 口腔内崩解片剂
WO2013169925A1 (en) Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
US20100086590A1 (en) Novel stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof
JP5787881B2 (ja) 腸溶性錠剤
JP6321131B2 (ja) アムロジピン含有配合錠の溶出性改善方法
JP6238831B2 (ja) バルサルタン含有錠剤及びその製造方法
AU2017339755B2 (en) Pharmaceutical compositions of 5-HT6 antagonist
JP2014114243A (ja) 安定な固形製剤の製造方法
JP2018030810A (ja) ゲフィチニブを有効成分とする医薬錠剤の製造方法
JP5204452B2 (ja) ビカルタミド含有製剤
BR102021013921A2 (pt) Composição compreendendo o dexlansoprazol
WO2016156124A1 (en) Pharmaceutical formulation comprising sembragiline
HK1151991B (en) Tablet having improved elution properties

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111209

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20111209

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20120113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121221

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151228

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5167389

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250